Equities Analysts Issue Forecasts for SAGE Q1 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman expects that the biopharmaceutical company will post earnings of ($1.03) per share for the quarter. The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics' Q2 2025 earnings at ($0.99) EPS and Q4 2025 earnings at ($0.98) EPS.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Several other research analysts have also recently issued reports on SAGE. Truist Financial cut their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a "hold" rating on the stock in a report on Wednesday, October 30th. Royal Bank of Canada upgraded Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price target on the stock in a report on Thursday, November 21st. HC Wainwright reiterated a "neutral" rating and issued a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Stifel Nicolaus reduced their target price on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a research note on Monday, December 16th. Finally, TD Cowen dropped their price target on Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating for the company in a research note on Thursday, November 21st. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $9.65.

Sage Therapeutics Stock Down 0.6 %

Shares of SAGE traded down $0.04 during trading hours on Thursday, hitting $7.14. The company had a trading volume of 1,943,315 shares, compared to its average volume of 2,832,859. The firm has a market cap of $436.75 million, a P/E ratio of -1.28 and a beta of 0.94. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $26.25. The stock's 50 day moving average price is $6.40 and its 200 day moving average price is $6.85.

Institutional Trading of Sage Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Caligan Partners LP purchased a new stake in shares of Sage Therapeutics during the fourth quarter valued at approximately $16,575,000. Boothbay Fund Management LLC purchased a new stake in Sage Therapeutics during the 4th quarter valued at $7,540,000. State Street Corp increased its holdings in shares of Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock worth $21,127,000 after purchasing an additional 451,377 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Sage Therapeutics by 63.7% in the fourth quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company's stock worth $6,004,000 after purchasing an additional 430,432 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Sage Therapeutics by 103.1% during the fourth quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company's stock valued at $2,509,000 after purchasing an additional 234,528 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.